Barrett’s metaplasia (BM) is a common pre-malignant condition with unknown population prevalence, but an increasing endoscopic incidence. BM develops in the context of gastro-oesophageal reflux and is a major risk factor for oesophageal adenocarcinoma, which develops from BM via a metaplasia–dysplasia–carcinoma pathway. Current treatment strategies aim to prevent the progression through this pathway with drug regimes and detect dysplasia early via endoscopic surveillance. Multiple imaging modalities and adjuncts have been employed to detect dysplastic epithelium in BM, including high-definition endoscopy, confocal endomicroscopy, narrow band imaging, chromoendoscopy and autofluorescence. Historically, oesophagectomy was the only potentially curative treatment option for oesophageal adenocarcinoma in the context of BM, but the last 10 years have seen a dramatic increase in the use of endoscopic resection and ablation technologies. Endoscopic mucosal resection, photodynamic therapy and radiofrequency ablation can be considered for treatment of high-grade dysplasia and early oesophageal adenocarcinoma.
Share this Article
Related Content In Gastrointestinal Oncology
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
touchREVIEWS in Oncology & Haematology. 2021;17(1):18-22 DOI: https://doi.org/10.17925/OHR.2021.17.1.18
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract, accounting for 0.1–3.0% of all GI malignancies, and 80% of all GI sarcomas.1–5 While GISTs can occur throughout the entire GI tract, with similar male/female incidence, 60% of cases usually present in the stomach, and about 30% in the small […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
European Oncology & Haematology. 2020;16(1):11
Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!